Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Market Cap: US$95.3b

Bristol-Myers Squibb Past Earnings Performance

Past criteria checks 2/6

Bristol-Myers Squibb has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 8.9% annually. Revenues have been growing at an average rate of 4.6% per year. Bristol-Myers Squibb's return on equity is 31.2%, and it has net margins of 11.4%.

Key information

4.66%

Earnings growth rate

3.49%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate4.57%
Return on equity31.16%
Net Margin11.38%
Next Earnings Update31 Jul 2025

Recent past performance updates

We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

May 05
We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

Recent updates

We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

May 05
We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession

Apr 22

Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold

Mar 25

Bristol-Myers Squibb: Why I'm Still Bullish

Mar 18
author-image

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 21

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Feb 07

Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain

Jan 31

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Dec 29
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Dec 20

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Dec 15
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

Nov 27
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

Nov 25

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Oct 28

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Oct 06

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Sep 27

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Sep 06

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15
Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Revenue & Expenses Breakdown

How Bristol-Myers Squibb makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:BMY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2547,6365,4197,4789,672
31 Dec 2448,300-8,9487,8659,782
30 Sep 2447,435-7,2588,0779,470
30 Jun 2446,509-6,5417,8919,200
31 Mar 2445,534-6,1487,8849,252
31 Dec 2345,0068,0257,6789,112
30 Sep 2344,9358,2857,8749,146
30 Jun 2345,1877,9637,7849,321
31 Mar 2345,8487,3117,6369,274
31 Dec 2246,1596,3277,7779,509
30 Sep 2246,7386,6777,7859,209
30 Jun 2247,1446,6177,7249,319
31 Mar 2246,9606,2517,8089,266
31 Dec 2146,3856,9947,65510,195
30 Sep 2145,468-5,4057,7479,371
30 Jun 2144,384-5,0797,7129,279
31 Mar 2142,810-6,2197,4429,182
31 Dec 2042,518-9,0157,61810,048
30 Sep 2039,395-446,6268,655
30 Jun 2034,862-5635,9217,737
31 Mar 2031,0069545,3996,868
31 Dec 1926,1453,4394,9696,066
30 Sep 1924,1735,6554,5495,281
30 Jun 1923,8576,2034,5685,185
31 Mar 1923,2885,1444,5855,245
31 Dec 1822,5614,9204,5236,253
30 Sep 1822,0371,4324,2305,184
30 Jun 1821,6003764,3275,109
31 Mar 1821,0409194,4384,958
31 Dec 1720,7761,0074,7496,085
30 Sep 1720,5704,2294,8964,697
30 Jun 1720,2384,5864,8774,589
31 Mar 1719,9654,8364,9294,513
31 Dec 1619,4274,4574,8154,477
30 Sep 1618,4713,3664,9474,366
30 Jun 1617,6182,8704,9774,310
31 Mar 1616,9101,5744,8714,181
31 Dec 1516,5601,5654,8314,037
30 Sep 1516,5311,7754,6974,001
30 Jun 1516,3831,7904,6253,896
31 Mar 1516,1092,2534,6283,869
31 Dec 1415,8792,0044,7173,913
30 Sep 1416,0622,7174,6663,715
30 Jun 1416,2062,6884,7343,690

Quality Earnings: BMY has a large one-off loss of $5.0B impacting its last 12 months of financial results to 31st March, 2025.

Growing Profit Margin: BMY became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BMY's earnings have grown by 4.7% per year over the past 5 years.

Accelerating Growth: BMY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BMY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.1%).

Return on Equity

High ROE: Whilst BMY's Return on Equity (31.16%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 08:20
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 47 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays